# Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

> **NCT00460083** · PHASE4 · COMPLETED · sponsor: **Ceragenix Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Elidel(R) (pimecrolimus 1%)
- **DEVICE:** EpiCeram(R) -ceramide based barrier repair cream

## Key facts

- **NCT ID:** NCT00460083
- **Lead sponsor:** Ceragenix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-12
- **Final completion:** 2008-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2008-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00460083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00460083, "Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00460083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*